NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

October 29, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Solid Tumor, AdultColorectal CancerNon Small Cell Lung CancerPancreatic CancerCRCNSCLCPancreas CancerMesotheliomaOvarian CancerOvarian NeoplasmsOvarian CarcinomaMesothelioma, MalignantMesothelioma; LungCancerTriple Negative Breast Cancer (TNBC)Renal Cell Carcinoma (Kidney Cancer)Head and Neck Squamous Cell Carcinoma HNSCC

Interventions

OTHER

Apheresis

Apheresis procedure performed for collection of PBMCs.

DIAGNOSTIC_TEST

Next Generation Sequencing (NGS)

NGS on tumor tissue and a matched normal sample for loss of heterozygosity in tumor tissue and tumor tissue markers.

DIAGNOSTIC_TEST

Long Range NGS HLA typing

Long range NGS on whole blood to determine germline HLA type.

Trial Locations (15)

10016

RECRUITING

NYU Langone Medical Center, New York

32224

RECRUITING

Mayo Clinic Jacksonville, Jacksonville

33136

RECRUITING

Moffitt Cancer Center, Tampa

43210

RECRUITING

The Ohio State University Comprehensive Cancer Center, Columbus

55905

RECRUITING

Mayo Clinic Rochester, Rochester

63110

RECRUITING

Washington University, St Louis

77030

ACTIVE_NOT_RECRUITING

MD Anderson Cancer Center, Houston

85054

RECRUITING

Mayo Clinic Hospital, Phoenix

85234

RECRUITING

Banner Health, Gilbert

90101

COMPLETED

City of Hope, Duarte

90404

RECRUITING

UCLA Medical Center, Santa Monica

92093

RECRUITING

University of California San Diego, La Jolla

94304

RECRUITING

Stanford University, Palo Alto

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

02114

ACTIVE_NOT_RECRUITING

Massachusetts General Hospital/Dana Farber Cancer Institute, Boston